Geographically, the global thiazide diuretics market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing incidences of hypertension-related disorders among the individuals and growing product penetration in the region. Furthermore, in 2030, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the rise in prevalence of diuresis, edema and other diuretic medical conditions, accompanied by the presence of leading market players in the region. Along with this, North America also leads in terms of clinical research, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant market share over the forecast period on account of the rapid increase in the number of cases and awareness about cardiovascular disorders in the region. As per the data published in the journal Annals of Global Health in 2020, cardiovascular diseases (CVD) are the leading cause responsible for deaths in Europe and accounts for 45% of the total number of deaths. More than 4 million individuals in Europe suffer death annually from cardiovascular diseases.
Get more information on this report: Download Sample PDF
The global thiazide diuretics market is further classified on the basis of region as follows:
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Our in-depth analysis of the global thiazide diuretics market includes the following segments:
By Distribution Channel
Ans: The increasing prevalence of hypertension and associated disorders and rising geriatric population are the key factors driving market growth.
Ans: The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2022-2030.
Ans: Strict healthcare regulations governing the market and the harmful effects of ionic imbalance caused by thiazide diuretics use are estimated to hamper market growth.
Ans: The market in Asia Pacific region will provide ample growth opportunities owing to the increasing incidence of hypertension-related disorders among the individuals.
Ans: The major players dominating the thiazide diuretics market are Pfizer Inc., Merck Sharp & Dohme Corp., Sanofi SA, and Bayer AG, among others.
Ans: The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by use, distribution channel, and by region.
Ans: With respect to distribution channel, the hospital pharmacies’ segment is anticipated to hold the largest market share owing to the preference of the population with hypertension and associated disorders choose hospital facilities for treatment.